Paper39232245
The pathogenesis of IgA nephropathy and implications for treatment.
Cheung CK and 5 others. Nat Rev Nephrol, 2025. Cited by 164 papers, by iCite.
Cite this record
ConductScience Library. The pathogenesis of IgA nephropathy and implications for treatment. Papers, record 39232245. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39232245
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glomerulonephritis, IGA | Major topic |
| Humans | |
| Immunoglobulin A | |
| Complement Activation | |
| B-Cell Activating Factor | |
| B-Lymphocytes | |
| Tumor Necrosis Factor Ligand Superfamily Member 13 |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| IA/CPHS/22/1/506541 | DBT-Wellcome Trust India Alliance | India | PubMed |
Source PubMed
References175
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37591292 | Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. | Lancet | 2023 | https://conductscience.org/library/papers/37591292 | PubMed |
| 2 | 37914086 | Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. | Kidney Int | 2024 | https://conductscience.org/library/papers/37914086 | PubMed |
| 3 | 38344739 | Novel Treatment Paradigms: Primary IgA Nephropathy. | Kidney Int Rep | 2024 | https://conductscience.org/library/papers/38344739 | PubMed |
| 4 | 91839 | IgA immune complexes in Henoch-Schönlein purpura. | Lancet | 1979 | https://conductscience.org/library/papers/91839 | PubMed |
| 5 | 38552841 | A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. | Kidney Int | 2024 | https://conductscience.org/library/papers/38552841 | PubMed |
| 6 | 30612739 | Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10. | Cell | 2019 | https://conductscience.org/library/papers/30612739 | PubMed |
| 7 | 38025243 | Targeting the Endothelin A Receptor in IgA Nephropathy. | Kidney Int Rep | 2023 | https://conductscience.org/library/papers/38025243 | PubMed |
| 8 | 3409549 | The bone marrow as production site of the IgA deposited in the kidneys of patients with IgA nephropathy. | Clin Exp Immunol | 1988 | https://conductscience.org/library/papers/3409549 | PubMed |
| 9 | 16757497 | IgA-containing immune complexes in the urine of IgA nephropathy patients. | Nephrol Dial Transplant | 2006 | https://conductscience.org/library/papers/16757497 | PubMed |
| 10 | 15156532 | Recurrent IgA nephropathy after renal transplantation. | Semin Nephrol | 2004 | https://conductscience.org/library/papers/15156532 | PubMed |
| 11 | 2063851 | The fate of aggregated immunoglobulin A injected in IgA nephropathy patients and healthy controls. | Am J Kidney Dis | 1991 | https://conductscience.org/library/papers/2063851 | PubMed |
| 12 | 33436510 | Associations of Genetic Variants Contributing to Gut Microbiota Composition in Immunoglobin A Nephropathy. | mSystems | 2021 | https://conductscience.org/library/papers/33436510 | PubMed |
| 13 | 36351458 | Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. | Lancet | 2022 | https://conductscience.org/library/papers/36351458 | PubMed |
| 14 | 21949093 | The pathophysiology of IgA nephropathy. | J Am Soc Nephrol | 2011 | https://conductscience.org/library/papers/21949093 | PubMed |
| 15 | 24922509 | Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). | PLoS One | 2014 | https://conductscience.org/library/papers/24922509 | PubMed |
| 16 | 27461177 | The human intestinal B-cell response. | Mucosal Immunol | 2016 | https://conductscience.org/library/papers/27461177 | PubMed |
| 17 | 6813005 | Detection of polymeric IgA in glomeruli from patients with IgA nephropathy. | Clin Exp Immunol | 1982 | https://conductscience.org/library/papers/6813005 | PubMed |
| 18 | 23739233 | Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. | Kidney Int | 2013 | https://conductscience.org/library/papers/23739233 | PubMed |
| 19 | 8157744 | Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death. | J Clin Pathol | 1993 | https://conductscience.org/library/papers/8157744 | PubMed |
| 20 | 36307926 | The role of complement in glomerulonephritis-are novel therapies ready for prime time? | Nephrol Dial Transplant | 2023 | https://conductscience.org/library/papers/36307926 | PubMed |
Cited by139
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 164 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42983718 | IgA nephropathy in a patient with 17α-hydroxylase/17,20-lyase deficiency caused by the CYP17A1 p. Y329fs mutation: a case report and review. | BMC Pediatr | 2026 | https://conductscience.org/library/papers/42983718 | PubMed |
| 42934562 | Prognostic value of the neutrophil percentage-to-albumin ratio in patients with IgA nephropathy. | BMC Nephrol | 2026 | https://conductscience.org/library/papers/42934562 | PubMed |
| 42909805 | Exosomal C3a initiates the NF-κB-dependent inflammatory axis in IgA nephropathy: a three-phase pilot study integrating clinical, in vivo, and in vitro evidence. | Clin Exp Nephrol | 2026 | https://conductscience.org/library/papers/42909805 | PubMed |
| 42903470 | Single-cell transcriptomic analysis of the terminal ileum identifies BCMA as a therapeutic target in IgA nephropathy. | Hlife | 2026 | https://conductscience.org/library/papers/42903470 | PubMed |
| 42899115 | Efficacy and safety of low-dose telitacicept in IgA nephropathy: a real-world study. | Clin Kidney J | 2026 | https://conductscience.org/library/papers/42899115 | PubMed |
| 42840445 | Mesenchymal stem cells: a potential therapeutic strategy for IgA nephropathy. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42840445 | PubMed |
| 42818608 | Prognostic value of serum total bilirubin-lipid ratios in patients with IgA nephropathy. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42818608 | PubMed |
| 42811306 | Targeted-release Budesonide (Nefecon) versus systemic glucocorticoids for IgA nephropathy: a placebo-anchored indirect treatment comparison of randomized controlled trials. | BMC Nephrol | 2026 | https://conductscience.org/library/papers/42811306 | PubMed |
| 42807446 | High complement activation index predicts renal progression in crescentic IgA nephropathy. | Front Immunol | 2026 | https://conductscience.org/library/papers/42807446 | PubMed |
| 42787250 | Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42787250 | PubMed |
| 42786735 | Smoking exposure and long-term progression of IgA nephropathy: a retrospective cohort study of 9,560 patients. | Ren Fail | 2026 | https://conductscience.org/library/papers/42786735 | PubMed |
| 42756351 | Tonsillar Tfh cells contribute to the pathogenesis of IgA nephropathy in collaboration with memory B cells. | Front Immunol | 2026 | https://conductscience.org/library/papers/42756351 | PubMed |
| 42746036 | Post-translational protein S-palmitoylation in renal tubular injury: mechanisms and therapeutic implications. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42746036 | PubMed |
| 42707564 | From immune dysregulation to renal injury: mechanistic insights and translational opportunities in immune-mediated nephropathies. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42707564 | PubMed |
| 42698355 | Sarsasapogenin Preserves Podocyte Integrity and Attenuates Renal Injury in Experimental IgA Nephropathy. | FASEB J | 2026 | https://conductscience.org/library/papers/42698355 | PubMed |
| 42687161 | Management strategies for post-transplant IgA nephropathy in kidney transplant recipients: a scoping review. | BMC Nephrol | 2026 | https://conductscience.org/library/papers/42687161 | PubMed |
| 42666627 | Beyond the alarm: unveiling the multifaceted role of IL-33 in kidney disease. | Front Immunol | 2026 | https://conductscience.org/library/papers/42666627 | PubMed |
| 42642725 | A comparative study on the clinicopathological features and short-term prognosis of IgA-dominant infection-related glomerulonephritis and IgA nephropathy. | BMC Nephrol | 2026 | https://conductscience.org/library/papers/42642725 | PubMed |
| 42639472 | Gut-kidney axis in IgA nephropathy: mechanisms linking microbiota dysbiosis to immune dysregulation, Gd-IgA1 generation, and renal injury. | Front Immunol | 2026 | https://conductscience.org/library/papers/42639472 | PubMed |
| 42633049 | Efficacy and safety of sibeprenlimab in IgA nephropathy: interim analysis of the China cohort in the phase 3 VISIONARY trial. | Clin Kidney J | 2026 | https://conductscience.org/library/papers/42633049 | PubMed |
Genes46
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39232245
GET https://conductscience.org/api/papers/v1/39232245/references?page=2